publication date: Nov. 20, 2015

Kantoff Named Chair of MSKCC Department of Medicine 


PHILIP KANTOFF was named chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center.

Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School since 1987 in a variety of capacities. He formally assumes his new position as George Bosl steps down from his role after 18 years. Kantoff will continue to see patients in addition to heading a program of laboratory-based research.

Kantoff was previously director of the Lank Center for Genitourinary Oncology, chief of the Division of Solid Tumor Oncology, vice chair of the Department of Medical Oncology, and chair of the Executive Committee on Clinical Research at Dana-Farber, as well as a professor of medicine at HMS. He was the Jerome and Nancy Kohlberg Endowed Chair at HMS, leader of the Dana-Farber/Harvard Cancer Center Prostate Cancer Program, and director of its Prostate Cancer Specialized Program of Research Excellence (SPORE) grant.

As director of the Lank Center, Kantoff oversaw programs of clinical care and research as well as laboratory research. His lab focused on the genetics and genetic epidemiology of prostate cancer, mechanisms of resistance to therapies, and the role of noncoding RNAs in prostate cancer as well as the discovery of biomarkers that may be useful prognostic tools and/or therapeutic targets. He served as a clinical researcher and principal investigator in significant trials devoted to the development of new therapeutic targets for men with advanced prostate cancer.

As professor of medicine at HMS since 2004, Kantoff’s research program focused on the molecular basis of genitourinary cancers and improved treatment … Continue reading 41-43 Kantoff Named Chair of MSKCC Department of Medicine

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.